|Day Low/High||1.70 / 1.85|
|52 Wk Low/High||1.08 / 3.25|
Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G.
Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company has received a Notice of Allowance from the...
Researchers at Augusta University show galectin-3 inhibitors improve PAH in animal models
Top line results of the NASH-FX trial to be reported in September 2016
Conference Call to Begin at 8:30 a.m. ET Today
United States District Court Dismisses Both Actions With Prejudice
Forum Uniquely Brings Together Leading Family Offices, Their Foundations and Sovereign Wealth Fund Representatives Seeking Impact Investment, Grant-Giving, and Philanthropy Opportunities Within Health and Life Sciences
Providence Cancer Center Submits IND for Phase 1b Trial
Proof-of-Concept Study to Determine Safety and Efficacy in 10 Patients With Moderate-to-Severe Plaque Psoriasis
Second Trial in GR-MD-02 Phase 2 Program Features Non-Invasive Endpoints and Shorter Treatment Duration; Data Readout Expected in the Third Quarter of 2016
Broad Coverage Includes Use of Various Pectin Compounds for Chronic Kidney Disease Associated with the Development of Fibrosis, Established Kidney Fibrosis, Chronic Lung Disease Associated with the Development of Fibrosis and Established Lung Fibrosis